VC-backed Fusion Pharmaceuticals seeks $125m from IPO: report

Canadian cancer radiotherapeutics specialist Fusion Pharmaceuticals is looking to raise US$125 million (C$170 million) from its initial public offering on Nasdaq.

Fusion Pharmaceuticals is looking to raise US$125 million (C$170 million) at the midpoint of the proposed pricing range of its initial public offering on Nasdaq, according to a report by Renaissance Capital. That would value the Hamilton, Ontario-based cancer radiotherapeutics company at about US$619 million (C$840 million). Founded in 2015, Fusion is backed by Adams Street Partners, Canada Pension Plan Investment Board, FACIT, Genesys Capital, HealthCap, JJDC, OrbiMed, Perceptive Advisors, Pivotal bioVenture Partners, Rock Springs Capital, Seroba Life Sciences, TPG Biotech and Varian Medical Systems.

Renaissance Capital